ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takeda, K.
Right arrow Articles by Gelfand, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takeda, K.
Right arrow Articles by Gelfand, E. W.
Eur Respir J 2005; 26:577-585
Copyright ©ERS Journals Ltd 2005

S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice

K. Takeda1, N. Miyahara1, T. Kodama1, C. Taube1, A. Balhorn1, A. Dakhama1, K. Kitamura2, A. Hirano2, M. Tanimoto2 and E. W. Gelfand1

1 Dept of Paediatrics, National Jewish Medical and Research Center, Denver, CO, USA. 2 Okayama University Medical School, Okayama, Japan.

CORRESPONDENCE: E. W. Gelfand, 1400 Jackson Street, Denver, CO 80206, USA. Fax: 1 3032702105. E-mail: gelfande{at}njc.org

Keywords: Airway hyperresponsiveness, eosinophils, neutrophils, S-carboxymethylcysteine

Received: July 30, 2004
Accepted June 10, 2005

S-carboxymethylcysteine (S-CMC) has been used as a mucoregulator in respiratory diseases. However, the mechanism of action of S-CMC on allergic airway inflammation has not yet been defined.

In the present study, BALB/c mice were initially sensitised and challenged to ovalbumin (OVA) and, weeks later, re-challenged with OVA (secondary challenge). S-CMC (5–100 mg·kg–1) was administered from 2 days before the secondary challenge through to the day of assay.

Mice developed airway hyperresponsiveness (AHR) 6 h after the secondary challenge and increased numbers of neutrophils were present in the bronchoalveolar lavage (BAL) fluid. At 72 h after secondary challenge, mice again developed AHR, but the BAL fluid contained large numbers of eosinophils. S-CMC treatment was found to reduce AHR and neutrophilia at 6 h, as well as eosinophilia and AHR at 72 h. These effects appeared to be dose dependent. Goblet cell hyperplasia, observed at 72 h, was reduced by S-CMC. In BAL fluid, increased levels of interferon-{gamma}, interleukin (IL)-12 and IL-10 and decreased levels of IL-5 and IL-13 were detected.

In conclusion, the data indicate that S-carboxymethylcysteine is effective in reducing airway hyperresponsiveness and airway inflammation at two distinct phases of the response to the secondary allergen challenge in sensitised mice.




This article has been cited by other articles:


Home page
J. Exp. Med.Home page
M. Okamoto, K. Takeda, A. Joetham, H. Ohnishi, H. Matsuda, C. H. Swasey, B. J. Swanson, K. Yasutomo, A. Dakhama, and E. W. Gelfand
Essential role of Notch signaling in effector memory CD8+ T cell-mediated airway hyperresponsiveness and inflammation
J. Exp. Med., May 12, 2008; 205(5): 1087 - 1097.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the European Respiratory Society.